Request for Covid-19 Impact Assessment of this Report

Take Action
Diagnostic and Biotech

Global Oncology Biosimilars Market Size study, By Indication (Atopic Dermatitis, Postoperative Immunosuppression, Ulcerative Colitis, Psoriasis, Keratoconjunctivitis, Others), By Drug Class (Cyclosporine, Tacrolimus, Pimecrolimus, Others), By Route of Administration (Oral, Topical, Parenteral), By End-Users (Hospitals, Specialty Clinics, Homecare, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and Regional Forecasts 2022-2028

  • BIZ4982919
  • 200 Pages
  • May 2022
  • Diagnostic and Biotech
Download Sample    Get Discount   
 
Global Oncology Biosimilars Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Oncology Biosimilars can be defined as a version of a known and proven biologic drug. These drugs are made from living things such as cells, tissues, or proteins. Biosimilars are more affordable alternatives to similar other drugs. Also, biosimilar offers similar safety and toxicity profile. Growing prevalence of cancer worldwide and increasing demand for biosimilar drugs due to affordability as well as recent partnerships and product launches from leading players are key drivers for growth of Oncology Biosimilars Market. For instance, according to World Cancer Research Fund – in 2020, around 18.1 million cancer cases were reported globally. Around 9.3 million cases were in men and 8.8 million in women. Further, Breast and lung cancers were most prevalent type of cancers worldwide, contributing 12.5% and 12.2% of all cancer cases reported in 2020. Moreover, in March 2019, the United States (U.S.) Food and Drug Administration (FDA) has approved new biosimilar from Pfizer Inc. named TRAZIMERA (trastuzumab-qyyp). This new drug is a biosimilar to Herceptin (trastuzumab). This new drug is intended for the treatment of breast cancer and Esophageal cancer. Further, in March 2022, Cipla Medpro, a wholly owned subsidiary of Cipla Limited, India entered in a partnership agreement with Madrid, Spain based mAbxience. Under this partnership both the companies would work towards bringing oncology and respiratory-related biosimilars to South Africa region. Also, growing spending on pharmaceuticals research and rising healthcare infrastructure in emerging economies are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, high cost associated with the drug development & distribution and complex process of drug development and approvals impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Oncology Biosimilars Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to rising R&D activities and increasing prevalence of cancer as well as presence of leading market players. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as growing number of pharmaceutical contract manufacturers and rising healthcare spending in the region, would create lucrative growth prospects for the Oncology Biosimilars Market across the Asia Pacific region.

Major market players included in this report are:

Pfizer Inc. (U.S.)

GlaxoSmithKline plc (U.K.)

Novartis AG (Switzerland)

Mylan N.V. (U.S.)

Teva Pharmaceutical Industries Ltd.(Israel)

Sanofi (France)

F. Hoffmann-La Roche Ltd. (Switzerland)

Zydus Cadila (India)

Lupin (India)

Amneal Pharmaceuticals LLC. (U.S.)

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Indication

Breast Cancer

Lung Cancer

Colorectal Cancer

Cervical Cancer

Blood Cancer

Others

By Drug Class

Monoclonal Antibodies

Granulocyte Colony-Stimulating Factor

Others

By Route of Administration

Intravenous

Subcutaneous

Others

By End-Users

Hospitals

Specialty Clinics

Homecare

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020

Base year – 2021

Forecast period – 2022 to 2028

Target Audience of the Global Oncology Biosimilars Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Chapter 1. Executive Summary

1.1. Market Snapshot

1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)

1.2.1. Global Oncology Biosimilars Market, by Region, 2020-2028 (USD Million)

1.2.2. Global Oncology Biosimilars Market, by Indication, 2020-2028 (USD Million)

1.2.3. Global Oncology Biosimilars Market, by Drug Class, 2020-2028 (USD Million)

1.2.4. Global Oncology Biosimilars Market, by Route of Administration, 2020-2028 (USD Million)

1.2.5. Global Oncology Biosimilars Market, by End-Users, 2020-2028 (USD Million)

1.2.6. Global Oncology Biosimilars Market, by Distribution Channel, 2020-2028 (USD Million)

1.2.7.

1.3. Key Trends

1.4. Estimation Methodology

1.5. Research Assumption

Chapter 2. Global Oncology Biosimilars Market Definition and Scope

2.1. Objective of the Study

2.2. Market Definition & Scope

2.2.1. Scope of the Study

2.2.2. Industry Evolution

2.3. Years Considered for the Study

2.4. Currency Conversion Rates

Chapter 3. Global Oncology Biosimilars Market Dynamics

3.1. Oncology Biosimilars Market Impact Analysis (2020-2028)

3.1.1. Market Drivers

3.1.1.1. Growing prevalence of cancer worldwide.

3.1.1.2. increasing demand for biosimilar drugs due to affordability.

3.1.1.3. Recent partnerships and product launches from leading players.

3.1.2. Market Challenges

3.1.2.1. high cost associated with the drug development & distribution.

3.1.2.2. Complex process of drug development and approvals.

3.1.3. Market Opportunities

3.1.3.1. Growing spending on pharmaceuticals research.

3.1.3.2. Rising healthcare infrastructure in emerging economies.

Chapter 4. Global Oncology Biosimilars Market Industry Analysis

4.1. Porter’s 5 Force Model

4.1.1. Bargaining Power of Suppliers

4.1.2. Bargaining Power of Buyers

4.1.3. Threat of New Entrants

4.1.4. Threat of Substitutes

4.1.5. Competitive Rivalry

4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2028)

4.2. PEST Analysis

4.2.1. Political

4.2.2. Economical

4.2.3. Social

4.2.4. Technological

4.3. Investment Adoption Model

4.4. Analyst Recommendation & Conclusion

4.5. Top investment opportunity

4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

5.1.1. Assessment of the overall impact of COVID-19 on the industry

5.1.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Oncology Biosimilars Market, by Indication

6.1. Market Snapshot

6.2. Global Oncology Biosimilars Market by Indication, Performance - Potential Analysis

6.3. Global Oncology Biosimilars Market Estimates & Forecasts by Indication 2018-2028 (USD Million)

6.4. Oncology Biosimilars Market, Sub Segment Analysis

6.4.1. Breast Cancer

6.4.2. Lung Cancer

6.4.3. Colorectal Cancer

6.4.4. Cervical Cancer

6.4.5. Blood Cancer

6.4.6. Others

Chapter 7. Global Oncology Biosimilars Market, by Drug Class

7.1. Market Snapshot

7.2. Global Oncology Biosimilars Market by Drug Class, Performance - Potential Analysis

7.3. Global Oncology Biosimilars Market Estimates & Forecasts by Drug Class 2018-2028 (USD Million)

7.4. Oncology Biosimilars Market, Sub Segment Analysis

7.4.1. Monoclonal Antibodies

7.4.2. Granulocyte Colony-Stimulating Factor

7.4.3. Others

Chapter 8. Global Oncology Biosimilars Market, by Route of Administration

8.1. Market Snapshot

8.2. Global Oncology Biosimilars Market by Route of Administration, Performance - Potential Analysis

8.3. Global Oncology Biosimilars Market Estimates & Forecasts by Route of Administration 2018-2028 (USD Million)

8.4. Oncology Biosimilars Market, Sub Segment Analysis

8.4.1. Intravenous

8.4.2. Subcutaneous

8.4.3. Others

Chapter 9. Global Oncology Biosimilars Market, by End-Users

9.1. Market Snapshot

9.2. Global Oncology Biosimilars Market by End-Users, Performance - Potential Analysis

9.3. Global Oncology Biosimilars Market Estimates & Forecasts by End-Users 2018-2028 (USD Million)

9.4. Oncology Biosimilars Market, Sub Segment Analysis

9.4.1. Hospitals

9.4.2. Specialty Clinics

9.4.3. Homecare

9.4.4. Others

Chapter 10. Global Oncology Biosimilars Market, by Distribution Channel

10.1. Market Snapshot

10.2. Global Oncology Biosimilars Market by Distribution Channel, Performance - Potential Analysis

10.3. Global Oncology Biosimilars Market Estimates & Forecasts by Distribution Channel 2018-2028 (USD Million)

10.4. Oncology Biosimilars Market, Sub Segment Analysis

10.4.1. Hospital Pharmacy

10.4.2. Retail Pharmacy

10.4.3. Online Pharmacy

10.4.4. Others

Chapter 11. Global Oncology Biosimilars Market, Regional Analysis

11.1. Oncology Biosimilars Market, Regional Market Snapshot

11.2. North America Oncology Biosimilars Market

11.2.1. U.S. Oncology Biosimilars Market

11.2.1.1. Indication estimates & forecasts, 2018-2028

11.2.1.2. Drug Class estimates & forecasts, 2018-2028

11.2.1.3. Route of Administration estimates & forecasts, 2018-2028

11.2.1.4. End-Users estimates & forecasts, 2018-2028

11.2.1.5. Distribution Channel estimates & forecasts, 2018-2028

11.2.2. Canada Oncology Biosimilars Market

11.3. Europe Oncology Biosimilars Market Snapshot

11.3.1. U.K. Oncology Biosimilars Market

11.3.2. Germany Oncology Biosimilars Market

11.3.3. France Oncology Biosimilars Market

11.3.4. Spain Oncology Biosimilars Market

11.3.5. Italy Oncology Biosimilars Market

11.3.6. Rest of Europe Oncology Biosimilars Market

11.4. Asia-Pacific Oncology Biosimilars Market Snapshot

11.4.1. China Oncology Biosimilars Market

11.4.2. India Oncology Biosimilars Market

11.4.3. Japan Oncology Biosimilars Market

11.4.4. Australia Oncology Biosimilars Market

11.4.5. South Korea Oncology Biosimilars Market

11.4.6. Rest of Asia Pacific Oncology Biosimilars Market

11.5. Latin America Oncology Biosimilars Market Snapshot

11.5.1. Brazil Oncology Biosimilars Market

11.5.2. Mexico Oncology Biosimilars Market

11.6. Rest of The World Oncology Biosimilars Market

Chapter 12. Competitive Intelligence

12.1. Top Market Strategies

12.2. Company Profiles

12.2.1. Pfizer Inc. (US)

12.2.1.1. Key Information

12.2.1.2. Overview

12.2.1.3. Financial (Subject to Data Availability)

12.2.1.4. Product Summary

12.2.1.5. Recent Developments

12.2.2. GlaxoSmithKline plc (U.K.)

12.2.3. Novartis AG (Switzerland)

12.2.4. Mylan N.V. (U.S.)

12.2.5. Teva Pharmaceutical Industries Ltd. (Israel)

12.2.6. Sanofi (France)

12.2.7. F. Hoffmann-La Roche Ltd. (Switzerland)

12.2.8. Zydus Cadila (India)

12.2.9. Lupin (India)

12.2.10. Amneal Pharmaceuticals LLC. (U.S.)

Chapter 13. Research Process

13.1. Research Process

13.1.1. Data Mining

13.1.2. Analysis

13.1.3. Market Estimation

13.1.4. Validation

13.1.5. Publishing

13.2. Research Attributes

13.3. Research Assumption

List of Tables

TABLE 1. Global Oncology Biosimilars Market, report scope

TABLE 2. Global Oncology Biosimilars Market estimates & forecasts by Region 2018-2028 (USD Million)

TABLE 3. Global Oncology Biosimilars Market estimates & forecasts by Indication 2018-2028 (USD Million)

TABLE 4. Global Oncology Biosimilars Market estimates & forecasts by Drug Class 2018-2028 (USD Million)

TABLE 5. Global Oncology Biosimilars Market estimates & forecasts by Route of Administration 2018-2028 (USD Million)

TABLE 6. Global Oncology Biosimilars Market estimates & forecasts by End-Users 2018-2028 (USD Million)

TABLE 7. Global Oncology Biosimilars Market estimates & forecasts by Distribution Channel 2018-2028 (USD Million)

TABLE 8. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)

TABLE 9. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)

TABLE 10. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)

TABLE 11. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)

TABLE 12. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)

TABLE 13. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)

TABLE 14. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)

TABLE 15. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)

TABLE 16. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)

TABLE 17. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)

TABLE 18. U.S. Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 19. U.S. Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 20. U.S. Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 21. Canada Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 22. Canada Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 23. Canada Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 24. UK Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 25. UK Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 26. UK Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 27. Germany Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 28. Germany Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 29. Germany Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 30. RoE Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 31. RoE Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 32. RoE Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 33. China Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 34. China Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 35. China Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 36. India Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 37. India Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 38. India Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 39. Japan Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 40. Japan Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 41. Japan Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 42. RoAPAC Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 43. RoAPAC Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 44. RoAPAC Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 45. Brazil Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 46. Brazil Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 47. Brazil Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 48. Mexico Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 49. Mexico Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 50. Mexico Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 51. RoLA Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 52. RoLA Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 53. RoLA Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 54. Row Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 55. Row Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 56. Row Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 57. List of secondary sources, used in the study of global Oncology Biosimilars Market

TABLE 58. List of primary sources, used in the study of global Oncology Biosimilars Market

TABLE 59. Years considered for the study

TABLE 60. Exchange rates considered

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Similar Reports

2017-2021 UK Hemostasis Diagnostics Market: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers

Complete report $6,100.  DataPack (test volumes, sales forecasts, supplier shares) $3,950.

Summary

This comprehensive report contains 409 pages, 35 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the UK coagulation testing market duri...

  • Publish Date: February 7, 2017
  • $750
View Details
2017-2021 US Hemostasis Diagnostics Market: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers

Complete report $9,600.  DataPack (test volumes, sales forecasts, supplier shares) $6,200.

Summary

This comprehensive report contains 424 pages, 37 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the US coagulation testing market during the...

  • Publish Date: February 7, 2017
  • $750
View Details
2017-2021 Immunohematology and Infectious Disease Screening Market: Competitive Analysis of Major Suppliers and Emerging Market Entrants

This new report from VPGMarketResearch.com provides strategic assessments of major blood banking product suppliers and emerging market entrants. The report presents analyses of major current and emerging suppliers in terms of their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.

Con...

  • Publish Date: February 7, 2017
  • $750
View Details
 
View More
 

Client Testimonials

2024 © Copyright Big Market Research